Constitutive activity and structural instability of the wild-type human H2 receptor

Journal of Neurochemistry

Volumn 71, Issue 2, 1998, Pages 799-807

  Alewijnse, Astrid E ^a   Smit, Martine J ^a,b   Hoffmann, Marcel ^a   Verzijl, Dennis ^a   Timmerman, Henk ^a   Leurs, Rob ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Constitutive activity; Down regulation; Histamine H2 receptor; Inverse agonism; Structural instability; Up regulation

Indexed keywords

BURIMAMIDE; CIMETIDINE; CYCLIC AMP; FAMOTIDINE; HISTAMINE; HISTAMINE H2 RECEPTOR; RANITIDINE;

AGONIST; ANIMAL CELL; ARTICLE; CHO CELL; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS;

EID: 0031784970     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.71020799.x     Document Type: Article

References (46)

1. Bertaccini G. and Coruzzi G. (1992) Histamine receptors in the digestive system, in The Histamine Receptor (Schwartz J. C. and Haas H. L., eds), pp. 193-230. Wiley-Liss, New York.
2. 2 receptors in insect Sf9 cells. Br. J. Pharmacol. 122, 867-874.
3. 2 receptors. Nature 236, 385-390.
4. Bradford M. M. (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding. Anal. Biochem. 72, 248-254.
5. 2 blocking drugs. Neurobiol. Aging 16, 523-530.
6. 1 receptor subtypes delineate residues underlying activation properties. J. Biol. Chem. 271, 28071-28076.
7. Chidiac P., Hebert T. E., Valiquette M., Dennis M., and Bouvier M. (1994) Inverse agonist activity of β-adrenergic antagonists. Mol. Pharmacol. 45, 490-499.
8. Coruzzi G. and Bertaccini G. (1989) Increased parietal cell sensitivity after chronic treatment with ranitidine in the conscious cat. Agents Actions 28, 215-217.
9. Costa T., Ogino Y., Munson P. J., Onaran O., and Rodbard D. (1992) Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol. Pharmacol. 41, 549-560.
10. 2 receptor antagonists in peptic ulcer. Drugs 44, 709-719.
11. 2 receptor. Biochem. Biophys. Res. Commun. 178, 1386-1392.
12. 2 receptor. Proc. Natl. Acad. Sci. USA 88, 429-433.
13. Gether U., Ballesteros J. A., Seifert R., Sanders-Bush E., Weinstein H., and Kobilka B. K. (1997) Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J. Biol. Chem. 272, 2587-2590.
14. 3 receptor. J. Neural Transm. 103, 1163-1175.
15. 2 dopamine receptors. Br. J. Pharmacol. 121, 731-736.
16. Heinflink M., Nussenzveig D. R., Grimberg H., Lupumeiri M., Oron Y., and Gershengorn M. C. (1995) A constitutively active mutant thyrotropin-releasing hormone receptor is chronically down-regulated in pituitary cells: evidence using chlordiazepoxide as a negative antagonist. Mol. Endocrinol 9, 1455-1460.
17. Kaminsky R., Moriarty T. M., Bodine J., Wolf A. E., and Davidson M. (1990) Effect of famotidine on deficit symptoms of schizophrenia. Lancet 335, 1351-1352.
18. Kenakin T. P. (1987) Competitive antagonism by partial agonists, in Pharmacologic Analysis of Drug-Receptor Interaction (Kenakin T. P., ed), pp. 232-236. Raven Press, New York.
19. Kenakin T. P. (1996) The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol. Rev. 48, 413-463.
20. 2 receptor gene. Genomics 37, 390-394.
21. 1B-adrenoceptor by ligands that act as inverse agonists. Biochem. J. 325, 733-739.
22. Lefkowitz R. J., Cotecchia S., Samama P., and Costa T. (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14, 303-307.
23. 2 receptor stably expressed in Chinese hamster ovary cells. Br. J. Pharmacol 112, 847-854.
24. 2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Lett. 399, 108-112.
25. Milligan G., Bond R. A., and Lee M. (1995) Inverse agonism: pharmacological curiosity or potential therapeutic strategy. Trends Pharmacol. Sci. 16, 10-13.
26. 2-receptor antagonists in peptic ulcer disease. Evidence for a prophylactic use. Drugs 47, 862-871.
27. Nordstedt C. and Fredholm B. B. (1990) A modification of a protein-binding method for rapid quantification of cAMP cell-culture supernatants and body fluid. Anal Biochem. 189, 231-234.
28. 2 receptor blockade. Gut 32, 1455-1460.
29. 2-adrenergic receptor is constitutively desensitized and phosphorylated. Proc. Natl Acad. Sci. USA 91, 2699-2702.
30. 2-adrenergic receptor. Extending the ternary complex model. Biochemistry 35, 13368-13377.
31. 2-adrenergic receptor. J. Biol. Chem. 268, 16483-16487.
32. Rosse R. B., Kendrick K., Tsui L. C., Fay McCarthy M., Collins J. P., Rosenberg P., Wyatt R. J., and Deutsch S. I. (1995) Famotidine adjunctive pharmacotherapy of schizophrenia: a case report. Clin. Neuropharmacol. 18, 369-374.
33. 2 receptor gene. Biochem. Biophys. Res. Commun. 179, 1470-1478.
34. Samama P., Bond R. A., Rockman H. A., Milano C. A., and Lefkowitz R. J. (1997) Ligand-induced overexpression of a constitutively active beta(2)-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice. Proc. Natl. Acad. Sci. USA 94, 137-141.
35. Scheer A. and Cotecchia S. (1997) Minireview: constitutively active G protein-coupled receptors: potential mechanisms of receptor activation. J. Recept. Signal Transduct. Res. 17, 57-73.
36. Schipani E., Jensen G. S., Pincus J., Nissenson R. A., Gardella T. J., and Juppner H. (1997) Constitutive activation of the cyclic adenosine 3',5'-monophosphate signaling pathway by parathyroid hormone (PTH)/PTH-related peptide receptors mutated at the two loci for Jansen's metaphyseal chondrodysplasia. Mol. Endocrinol. 11, 851-858.
37. Schütz W. and Freissmuth M. (1992) Reverse intrinsic activity of antagonists on G protein-coupled receptors. Trends Pharmacol. Sci. 13, 376-380.
38. 2 receptors. Proc. Natl. Acad. Sci. USA 93, 6802-6807.
39. 2 receptor contains positive and negative signals important for signal transduction and receptor down-regulation. J. Neurochem. 67, 1791-1800.
40. Spiegel A. M. (1996) Defects in G protein-coupled signal transduction in human disease. Annu. Rev. Physiol. 58, 143-170.
41. Sterk G. J., van der Goot H., and Timmerman H. (1987) Studies on histaminergic compounds. VI. Synthesis and structure-activity relationships of a series of cimetidine and impromidine congeners. Eur. J. Med. Chem. 22, 427-432.
42. 2 receptor mediating inhibition of arachidonate release and activation of cAMP accumulation. Proc. Natl. Acad. Sci. USA 89, 2649-2653.
43. 1 receptor. I. Gene cloning, characterization, and tissue expression revealed by in situ hybridization. J. Neurochem. 62, 507-518.
44. 2 receptor: gene cloning, tissue expression and chromosomal localization of its human counterpart. Biochem. Biophys. Res. Commun. 211, 570-577.
45. Westphal R. S., Backstrom J. R., and Sanders-Bush E. (1995) Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization. Mol. Pharmacol. 48, 200-205.
46. 2-antagonists. Dig. Dis. Sci. 35, 976-983.